Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer
National Institute for Health and Clinical Excellence
Record ID 32006000315
English
Authors' objectives:
The aim of this report is to review capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer.
Authors' recommendations:
1 Guidance
1.1 The following are recommended as options for the adjuvant treatment of patients with stage III (Dukes' C) colon cancer following surgery for the condition: - capecitabine as monotherapy - oxaliplatin in combination with 5-fluorouracil and folinic acid.
1.2 The choice of adjuvant treatment should be made jointly by the individual and the clinicians responsible for treatment. The decision should be made after an informed discussion between the clinicians and the patient; this discussion should take into account contraindications and the side-effect profile of the agent(s) and the method of administration as well as the clinical condition and preferences of the individual.
Authors' methods:
Systematic review
Details
Project Status:
Completed
URL for project:
http://www.nice.org.uk/page.aspx?o=307811
Year Published:
2006
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England
MeSH Terms
- Antineoplastic Combined Chemotherapy Protocols
- Deoxycytidine
- Organoplatinum Compounds
- Colonic Neoplasms
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Clinical Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.